Physician profile
Carrie Wright
NPI 1932519808
$1,921.35
in general payments reported to CMS, 2019-2025
15 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.47 · 2021: $885 · 2022: $72.74 · 2023: $94.86 · 2024: $502 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.52 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $681.34 | 2020-2023 | |
| Alcon Vision LLC | $193.40 | 2021-2025 | Rocklatan, Argos, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $161.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $154.42 | 2023-2025 | Lumigan |
| Dompe US, INC. | $146.34 | 2021-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $137.92 | 2024 | Tecnis Iol |
| Atricure, INC. | $135.62 | 2024 | |
| Bausch & Lomb Americas INC. | $73.17 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $72.74 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.75 | 2024-2025 | |
| Biotissue Holdings INC. | $37.85 | 2025 | |
| Amgen INC. | $24.05 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $21.33 | 2020 | |
| Kala Pharmaceuticals, INC. | $19.62 | 2021 | |
| Oyster Point Pharma, INC. | $19.35 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.